=Quest Diagnostics (DGX) reported earnings on reported earnings on Thur 21 Oct 21 (b/o)

 

Quest Diagnostics beats by $0.90, beats on revs; raises FY21 EPS above consensus, revs above consensus

• Reports Q3 (Sep) earnings of $3.96 per share, excluding non-recurring items, $0.90 better than the S&P Capital IQ Consensus of $3.06; revenues fell 0.6% year/year to $2.77 bln vs the $2.52 bln S&P Capital IQ Consensus.
• Co issues raised guidance for FY21, sees EPS of $13.50-13.90 from $11.65-12.35, excluding non-recurring items, vs. $12.34 S&P Capital IQ Consensus; sees FY21 revs of $10.45-10.65 bln from $9.84-10.09 bln vs. $10.13 bln S&P Capital IQ Consensus.

Earnings this week : Oct 18 - 22, 21 (wk 42)

Monday (Oct 18)

• Morning:  ACI PHG STT
• Afternoon: ELS FNB HXL STLD ZION

Tuesday (Oct 19)

• Morning: BK CBSH DOV ERIC FITB FMBI HAL IRDM JNJ KSU MAN ONB PM PG SBNY SI SYF SNV TRV
• Afternoon:  CNI FULT HWC IBKR ISRG MRTN NBHC NFLX OMC LRN UAL UCBI WDFC WTFC

Wednesday (Oct 20)

• Morning:  ABT ANTM ASML BKR BIIB BOKF CP CFG CMA FHN FCFS KNX LAD MTB MKTX MSM NDAQ NEE NEP NTRS BPOP VZ WSO WGO
• Afternoon:  CNS CCI CSX CVBF DFS EFX EEFT FR GL GGG IBM KALU KMI LRCX LSTR LVS OMF PPG XM REXR RLI SLM SEIC SLG STL FTI THC TSLA TCBI UFPI UMPQ VMI

Thursday (Oct 21)

• Morning: ABB ALK ALLE ALLY AAL T AN BANC BKU BX GTLS CROX DHR DOW EWBC FAF FCX GATX GPC HRI HOMB IPG IQV KEY LNN MMC NUE NVR PPBI POOL PDS DGX RCI SASR SNA SON LUV TSCO TPH TRN UNP VLO WBS
• During Market Hours: WABC
• Afternoon:  ASB OZK BJRI SAM CSL CE CMG BOOM FFBC GBCI INTC MAT OLN PBCT PSMT RHI SNAP SIVB VICR WRB WAL WHR WSFS

Friday (Oct 22)  

• Morning:  AIMC AXP ALV CLF FHB GNTX HCA HON RF ROP SLB STX SMPL VFC

Quest Diagnostics (DGX) reported earnings on Tue 23 Oct 2018 (b/o)

** charts before earnings **

 

** charts after earnings **

 

Quest Diagnostics reports EPS in-line, misses on revs; lowers FY18 guidance  

Reports Q3 (Sep) earnings of $1.68 per share, in-line with the S&P Capital IQ Consensus of $1.68; revenues rose 1.8% year/year to $1.89 bln vs the $1.95 bln S&P Capital IQ Consensus. Co updates guidance for FY18, sees EPS of $6.53-6.60 (Prior $6.53-6.67), excluding non-recurring items, vs. $6.60 S&P Capital IQ Consensus; sees FY18 revs of ~$7.62 bln (Prior $7.7-7.74 bln) vs. $7.71 bln S&P Capital IQ Consensus. "We had a productive quarter, announcing three acquisitions and a Professional Lab Services agreement. We are updating our full-year revenue guidance to reflect lower than expected revenue performance this year, which has been affected in large part by industry headwinds we called out in the previous quarter. Looking ahead, our acquisition pipeline, along with our expanding health plan access, including UnitedHealthcare beginning January 1, position us well for growth in 2019."

Earnings this week : Oct 22 - 26, 18 (wk 43)

With 17% of the S&P 500 having reported quarterly results, reported earnings are up 22%; 81% have beat on the bottom line but only 51% have traded higher in response.

This week marks the first of three very heavy weeks of earnings reports -- almost 1/3 of the S&P 500 will report quarterly results.

Monday (October 22):

• Pre-Market: HAL, HAS, IQV, KMB, LII, PII
• After-Hours: ACC AMTD BRO CDNS CR ELS HLX HMST HNI HSTM HXL IBTX LOGI MC NBTB RNST SFNC SLM SPN SSB ZION

Tuesday (October 23):

• Pre-Market: ABG ALKS ARCH ASTE  ATI AVY AXE BIIB  CAT CIT CNC DGX EDU FBC FCB FITB FNB GATX GLW GPK HBAN HOG HUBB JBLU LMT LPT MBFI MCD MMM NEE PCAR  PHM PNR PPBI RF SLCA SNV TRU UTX VZ WAT XRX
• After-Hours:  AGR AMP BXMT CB CHFC CNI COF CSGP CSL EQR EW FCF FMBI HA HIW IEX ILMN IRBT JNPR LRN MANH MKSI NAVI NBHC NDLS NTB NWE RHI ROIC RRC SEIC SIX STL TER TRMK TSS TXN UCBI UMBF USNA VAR VMI WRB ZIXI

Wednesday (October 24):

• Pre-Market: AB ALXN APH AVX BA BABY BCO BKU BOKF BPOP BSX CHKP CRS DTE EVR FCX FSV GD GRA HLT IR ITW LAD LH MHO MKTX NDAQ NOC NSC NYCB OC PB POL QSR RES ROL SCHN SCL SIRI SLAB SLGN SMPL STM T TDY THR TMO TNC TPH TRVG TUP TZOO UMC UPS
• After-Hours:  ABX AEM AFL AGNC AHL AKR ALGN ALGT AMD ANIK ARI ASGN AX AXS AZPN CCMP CLB CLGX CLS CMRE CTXS CURO  CUZ CVBF CVRR DLB DRE ECHO EFX EIG ELY EQC ETH F FARO FFIV FNF FR FTI FWRD GG GGG GHL ICLR KN KRA KRC LJPC LM LSTR LVS MEOH MLNX MSA MSFT MTH NEU NGD NGVT NOW OII ORLY PKG PLXS PS PTC RJF SAVE SITC SNBR SRPT SUI TILE TMK TRN TSLA UNM V VRTX WHR WPG WRI WSBC XLNX  (largest:  Ford Motor (F), Microsoft (MSFT), Visa (V), Advanced Micro (AMD) and Tesla (TSLA) )

Thursday (October 25):

• Pre-Market: AAL AAN ABB AEP AIMC ALK ALLE ALLY ARD ASPS AXTA BANC BC BEN BMS BMY BUD BWA CCE CELG CFR CFX CMC CMCSA CME CMS COLB COP COR COWN CPG CRI CRR CSTM CTS DLX DNKN EIGI EME ENTG EQM EQT FAF FBP FCFS FCN GLOP GPI GRUB GWB HEES HSY IMAX IP IRDM IRM KIM KKR LANC LAZ LDOS LEA LECO LKQ LUV MCK MCRN MMC MMYT MNRO MO MRK MTRN NEM NLSN NOK NRZ NVCR NVT OAK OCN ODFL ORI PAG PATK PDS PRLB PTEN PX RCL RS RTN SAH SCG SHOP SHW SILC SJR SPG SPGI SWK SXC TAL TECK THRM TROW TSCO TWTR  UBS UBSI UNP USG VC VLO VLP VLY WM WNS WSO WST WWE XEL
• After-Hours:  ACTG AJG AKS AMZN AQ ARLO AUY AVT BGG BMRN BOOM BOOT BVN BYD CA CBLK CENX CERN CINF CLD CMG COLM CPT CUBE CUBI CVA CXP CY DECK DFS DLR DORM ELLI EMN ENVA EXPE FBHS FE FHB FII FIX FLEX FSLR FTV GCAP GDI GILD GOOG HIG HLI HTA HTH HUBG INT INTC INVA ISBC JEF KEX LEG LMAT LOGM LPLA LSCC MAT MERC MHK MMSI MPWR MSTR NATI NOV NR NTGR OFC OMCL OSIS PFG PFPT POWI PRO PSMT REG RGA RMD RSG SAM SBCF SGEN SIGI SIVB SNAP SPSC SWN SYK TMST UHS VCRA VLRS VRSN VVI WDC WRE

Friday (October 26):

• Pre-Market:  ALV AON B CHTR CL COG COL FELE GBX GRC GT GVA LPNT MCO PFS POR PSX PSXP R ROP SBSI SMP TEN TOT  VRTS VTR WETF WY ZBH

Quest Diagnostics (DGX) reported earnings on Tue 24 July 2018 (b/o)

**  before earnings **

** charts after earnings **

 

Quest Diagnostics misses by $0.01, misses on revs; guides FY18 EPS below consensus, revs in-line

• Reports Q2 (Jun) earnings of $1.75 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus of $1.76; revenues rose 3.0% year/year to $1.92 bln vs the $1.95 bln Capital IQ Consensus.
• Co issues guidancefor FY18, sees EPS of $6.53-6.57, excluding non-recurring items, vs. $6.61 Capital IQ Consensus Estimate and prior guidance of $6.50-6.70; sees FY18 revs of $7.70-7.74 bln vs. $7.72 bln Capital IQ Consensus Estimate and prior guidance of $7.70-7.77 bln.

UnitedHealth (UNH) : partnerships with Quest Diagnostics (DGX) and LabCorp (LH)

   

 

UnitedHealth establishes long-term strategic partnerships with Quest Diagnostics (DGX) and LabCorp (LH)

• UnitedHealthcare and Quest Diagnostics have established a long-term strategic partnership as the two organizations focus on ways to create more personalized care recommendations and a simpler consumer experience for the more than 48 million people enrolled in UnitedHealthcare plans. Quest will be in network for all UnitedHealthcare plan participants beginning Jan. 1, 2019. Quest has 6,000 patient access points and will be in network nationwide for all plan participants beginning Jan. 1, 2019.
• UnitedHealthcare and LabCorp renewed their long-term strategic partnership. LabCorp will continue to serve as UnitedHealthcare's exclusive national laboratory provider until Jan. 1, 2019. LabCorp offers nearly 5,000 frequently requested and specialty tests.

Quest Diagnostics (DGX) : Medicare proposes reimbursement cuts

Shares of Quest Diagnostics and its biggest rival LabCorp are falling sharply today in reaction to proposed Medicare reimbursement cuts that have been described by some analysts as "draconian."

 

The market for medical testing services is dominated by two players, Quest Diagnostics (DGX) and LabCorp (LH). The two companies each run a large chain of laboratories that conduct a slew of medical tests that help doctors diagnose and treat patients.

Late Friday, the Center for Medicare and Medicare Services released draft Medicare reimbursement rates for 2018 that were far worse than anyone expected. The word “draconian” has been used in several research notes.

Quest Diagnostics (DGX) reported earnings on Thur 20 Apr 2017 (b/o)

• #15 on 4/19 (just before)

** charts before earnings **

 

** charts after earnings **

 

Quest Diagnostics beats by $0.15, beats on revs; raises FY17 EPS guidance, reaffirms FY17 revs outlook:

• Reports Q1 (Mar) earnings of $1.33 per share, excluding non-recurring items, $0.15 better than the Capital IQ Consensus of $1.18; revenues rose 1.9% year/year to $1.9 bln vs the $1.87 bln Capital IQ Consensus.
• "Growth in the quarter was driven by expanding relationships with hospital health systems. Our agreement with PeaceHealth in the Pacific Northwest announced in the first quarter will further bolster growth later in the year."
• Co issues guidance for FY17, sees EPS of $5.45-5.60 (Prior $5.37-5.52), excluding non-recurring items, vs. $5.46 Capital IQ Consensus Estimate; sees FY17 revs of $7.64-7.72 bln vs. $7.67 bln Capital IQ Consensus Estimate. The company revised its diluted EPS estimates for full year 2017 results, reflecting higher than expected excess tax benefit related to stock-based compensation in the first quarter of 2017